Aridis Pharmaceuticals, a US biopharmaceutical company applying proprietary technologies to produce novel anti-infectives, has appointed Paul-Andre de Lame, as Chief Medical Officer.
Dr de Lame is an intensive care medical doctor with experience in cardiovascular medicine and infectious diseases. After several years in clinical practice as an anaesthesiologist and intensive case specialist, he joined Merck where he was charged with furthering the development of enalapril (Vasotec/Renitec) and imipenem-cilastatin (Tienam/Primaxin), then joined Warner Lambert-Parke Davis, where he was instrumental to the success of atorvastatin (Lipitor).
After that he founded Anabase International, which provides regulatory and clinical research services, and later, was co-founder and Chief Medical Officer of Cardiokine.
